Rivaroxaban for acute DVT

In this large randomized trial of patients with acute DVT, rivaroxaban (oral Xa inhibitor) was non-inferior to lovenox (bridged to coumadin) in the primary outcome of recurrent DVT, with the same incidence of bleeding. After 6-12 months of treatment, those that continued on rivaroxaban had significantly fewer recurrent DVTs than those that continued on placebo. Rivaroxaban is non-inferior to lovenox/warfarin for acute DVT, and better than placebo for ongoing longer term treatment (abstract). It is not currently FDA approved in the US but is under review.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment